CORDIS
EU research results

CORDIS

English EN
Automatic detection of disease related molecular cell activity

Automatic detection of disease related molecular cell activity

Objective

Many common diseases currently require that samples be sent to remote labs for diagnosis. This is costly and takes time, increasing patient anxiety and delaying the start of treatment. This project will make it feasible to carry out automatic, accurate diagnosis at the local doctor's office. This will be achieved using bio-marker mRNA detection. Compared to commonly used approaches, mRNA detection avoids false positive results and has a high sensitivity. It can currently be used to detect cancer and a range of respiratory diseases, to mention a few. New bio-markers are developed every day. The partners have already developed prototype technology which partly demonstrates a microsystem operation of the mRNA approach.

The project will build on this, providing the innovation needed to transform a promising technology to an integrated system suitable for practical use at point-of-care:
- Provide support for all stages: cell concentration, lysis, purification, sample collection, reagent mixing, amplification and detection.
-Develop disposable polymer chips for use in the portable instrument, including technology for storing all needed reagents on these chips.
-Develop reliable techniques for multi-channel parallel detection (crucial for recognising disease signatures).
-Address factors such as reliability, usability and cost which are crucial to acceptance by health care professionals.

System accuracy will be validated on the specific case of HPV (the virus causing cervical cancer), by comparing with macroscopic results and alternative methods used at laboratories. The consortium includes two research institutes and two industrial firms (both SMEs), who have extensive experience with mRNA techniques, and are motivated to commercialise results. They will be assisted by a hospital acting as end user, validating system usability and clinical accuracy.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STIFTELSEN SINTEF

Address

Strindveien 4
7465 Trondheim

Norway

Administrative Contact

Participants (5)

Sort alphabetically

Expand all

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG

Germany

BIOFLUIDIX GMBH

Germany

INSTITUT FUER MIKROTECHNIK MAINZ GMBH

Germany

NORCHIP AS

Norway

THE COOMBE WOMEN'S HOSPITAL

Ireland

Project information

Grant agreement ID: 017319

  • Start date

    1 December 2005

  • End date

    30 November 2008

Funded under:

FP6-NMP

  • Overall budget:

    € 2 779 600

  • EU contribution

    € 1 600 000

Coordinated by:

STIFTELSEN SINTEF

Norway